Streetbeat News

Regulatory

MTNB

Matinas Biopharma announced that researchers from the University of Minnesota Medical School have published results from the Phase 2 EnACT trial evaluating Mat2203 for Cryptococcal Meningitis. The results were published as a major article and editor's choice in Clinical Infectious Diseases.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2023 | 11:32 am

SXTP

60 Degrees Pharmaceuticals has received an additional US patent for Tafenoquine, a drug used for the prevention of Plasmodium Falciparum Malaria. The patent will strengthen the company's intellectual property rights and potentially increase its market share.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2023 | 11:31 am

VINC

Vincerx Pharma has announced that the FDA has cleared its Investigational New Drug (IND) application for VIP943.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2023 | 11:30 am

BTAI

The FDA has granted a Type B/Breakthrough Guidance meeting to Bioxcel Therapeutics for its TRANQUILITY trial program, scheduled for October 11, 2023, according to an 8K filing.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2023 | 11:09 am

FULC

The FDA has lifted the clinical hold on Fulcrum Therapeutics' FTX-6058 for Sickle Cell Disease. This allows the company to proceed with its clinical trials.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2023 | 11:01 am

TSLA

Tesla Inc (NASDAQ:TSLA) is reportedly closer to making its debut in India, with spy shots of the Model Y at Mahindra’s Pune Test Facility fueling speculation. The company has faced challenges entering the Indian market, including steep import taxes and the government's insistence on a local manufacturing unit. However, Tesla has recently committed to a local manufacturing hub. The Model Y's Indian debut is expected between the second and third quarters of 2024.

Portfolio Pulse from Shomik Sen Bhattacharjee

August 22, 2023 | 10:20 am

IXHL

Incannex Healthcare has received FDA approval to conduct IHL-42X Phase 2/3 trial in the US for obstructive sleep apnea patients who are non-compliant, intolerant, or naive to positive airway pressure treatment.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2023 | 10:16 am

BDSX

Biodesix's new analysis from the ORACLE study showed that patients with benign lung nodules managed with the Nodify XL2 test were 74% less likely to undergo unnecessary invasive procedures compared to the control group. This represents a 51% relative increase in cancer diagnosis rate. The proportion of patients sent to CT surveillance with malignant nodules did not differ between the Nodify XL2 group and the control group.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2023 | 10:05 am

TSLA

Tesla has been granted U.S. Patent #11734095, which pertains to a system and method for handling errors in a vehicle neural network processor. This could potentially enhance the company's autonomous driving technology.

Portfolio Pulse from Charles Gross

August 22, 2023 | 9:30 am

QCLN

Mary Trump, niece of former President Donald Trump, has warned that the 2024 general election could be the last free and fair election if President Joe Biden and the Democrats do not win. She also discussed the results of a recent CBS/YouGov poll, which showed that 71% of Donald Trump's voters trust him more than their own family and friends. The First Trust NASDAQ Clean Edge Green Energy Index Fund (NASDAQ:QCLN) was mentioned in the context of Biden's economic agenda, which includes measures to combat climate change and incentivize domestic tech manufacturing.

Portfolio Pulse from Shanthi Rexaline

August 22, 2023 | 8:24 am